Transferring flu protection

Two independent teams have shown proof of concept that gene transfer could be used to establish broad protection against influenza A viruses.^1,2 Both laboratories are working to move their influenza A virus hemagglutinin-expressing vectors into humans for immunogenicity and safety testing.

Despite the availability of flu vaccines, the morbidity and mortality associated with influenza A-triggered seasonal and pandemic flu outbreaks are still high. Multiple groups have identified broadly neutralizing antibodies that target a range of influenza virus types and immunotherapies based on such antibodies that could be used as prophylactics or as treatments for already infected patients.^3,4...